Advertisement

The New Attitude of the European Regulatory Authorities About Herbal Medicinal Products

  • 2 Citations

Abstract

In 1997, an ad hoc Herbal Medicinal Products Working Group (HMPWG) was established at the European Medicines Evaluation Agency in order to provide guidance for applicants and prepare recommendations on the criteria for the assessment of quality, safety, and efficacy of herbal medicinal products. The following topics were addressed in a detailed document containing several notes for guidance, comments, or points to consider: Notice to Applicants (presentation and content of the application dossier), quality guidance (agricultural production, requirements of active herbal substances and herbal medicinal products, and Type I and Type II variations), and preclinical and clinical assessment (giving particular emphasis to taking the existing scientific literature into account in order to avoid unnecessary animal tests and clinical trials in humans). Details and implications of these documents are presented here.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 189

This is the net price. Taxes to be calculated in checkout.

References

  1. 1.

    Law J. Making sense of herbal medicines. Scrip Magazine. May 1999;37–39.

  2. 2.

    Biffignandi P. Nutraceuticals and functional foods: a consumer-driven regulatory issue. ESRA Rapporteur. 1999;6(5):24–27.

  3. 3.

    Bloch A, Thomson CA. Position of the American Dietetic Association: Phytochemicals and functional foods. J Nutraceuticals, Functional Med Foods. 1997;1:33–45.

  4. 4.

    Dichek B. Enhancing the effects of nutraceuticals. Scrip Magazine, May 1999, p. 35.

  5. 5.

    Steinhoff B. The contribution of the European Scientific Cooperative on Phytotherapy and World Health Organization monographs. Drug Inf J. 1999;33:17–22.

  6. 6.

    FDA. Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drugs and Biological Products. Rockville, MD: Food and Drug Administration; May 1998.

  7. 7.

    Artiges A. Pharmacopoeial standards for herbal medicinal products in Europe. European Phytojournal. 1999. (www.ex.ac.uk/phytonet/phytojournal/)

Download references

Author information

Correspondence to Paolo M. Biffignandi MD, PhD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Biffignandi, P.M., Carletto, L. The New Attitude of the European Regulatory Authorities About Herbal Medicinal Products. Ther Innov Regul Sci 34, 801–808 (2000). https://doi.org/10.1177/009286150003400316

Download citation

Key Words

  • Herbal drugs
  • Europe
  • Regulatory affairs
  • European Medicines Evaluation Agency
  • Summary of Product Characteristics